Clinical Trials Browser

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Nasopharyngeal Carcinoma

HR+HER2- Breast Cancer

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

HER 2 Positive Gastric Cancer

Stomach Neoplasms

Breast Neoplasms

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Advanced Solid Tumors

Biliary Tract Neoplasms, Cholangiocarcinoma

Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

HER2-positive Gastric Cancer

HER2-positive Breast Cancer

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Adenocarcinoma, Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Advanced Solid Tumour

Breast Neoplasms

Pancreatic Neoplasms

Clinical Trials

GLOW

HERIZON-GEA-01

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

MK-3475-06C

ASPEN-09-03

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

BREnnA

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

LUCERNA

STAR-221

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

MK-2870-010

Pan Tumor Rollover Study

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

PARC